---

August 22, 2019.

Abu Dhabi based, global pharmaceutical manufacturer, Neopharma announced that it has entered into a definitive agreement through its Japanese subsidiary neoALA co. Ltd for the acquisition of the Japanese injectable business and related assets belonging to Kyowa (Kyowa Pharmaceutical Industry Co., Ltd.), subsidiary of pharma major Lupin Limited.
Under the terms of the agreement, Neopharma has acquired all the issued and outstanding share capital in Kyowa Criticare Co. Ltd from Lupin. The plant and associated facilities are based out of Atsugi, Japan and has been engaged in sales and contract manufacturing of injectable products to meet various medical needs.
The facility acquisition is a part of the global expansion drive for the UAE - based drug maker looking to establish itself as a global pharmaceutical manufacturer of high-quality medications at affordable prices. Currently Neopharma group manufactures and supplies API and finished dose formulations in over 50 global markets. Over the last few years Neopharma has made several major investment announcements that will position the company for future growth.

Suresh Nandiraju, Chief Operating Officer of Neopharma, said “This acquisition is synergetic and will strengthen our product offerings in the Japanese market, a focus market for Neopharma group for driving long-term, sustainable growth by leveraging our global presence.”

“We believe that Neopharma group is the right partner for Kyowa Criticare as they appreciate the strategic importance of this business unit and would be able to deliver value to business partners and customers, leveraging Kyowa Criticare’s people who are critical assets,” said Fabrice Egros, President Lupin APAC and Representative Director – Kyowa.

About Neopharma
neo ALA Co. Ltd. is 100% subsidiary of Neopharma Group, one of the largest pharmaceutical companies in the MENA region with subsidiaries in USA, Japan, Brazil, UK and India. A vertically integrated business, comprising of Key intermediaries, API, R&D and Formulation facilities in regulated and emerging markets. Neopharma's global presence is supported by 8 manufacturing facilities spread across 4 continents delivering a wide range of branded and generic formulations, and active pharmaceutical ingredients (APIs). For further information, log on to: www.neopharma.com

About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).
For the financial year ended 31st March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

For Enquiries:
Neopharma LLC; Tel: +9712 550 1000 www.neopharma.com neopharma@neopharma.com